Sentinel to Transform Drug Development and Oversight - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Sentinel to Transform Drug Development and Oversight
FDA is modernizing adverse-event reporting as part of a revolution in drug-safety assessment.

Pharmaceutical Technology
Volume 32, Issue 8

Distributed network

This expansion of AERS, however, is not designed to build a giant FDA health-information database for medical-product monitoring. Instead, the agency will expand postmarket surveillance by accessing data on drug use, patient outcomes, and specific safety issues held by private health plans, insurance companies, database operators, government agencies, and medical-products manufacturers. The aim is to negotiate contracts and partnerships with these existing electronic databases to establish a national, integrated, electronic distributed network for monitoring medical-product safety. By using a distributed network, all the personal medical data remains behind firewalls, thus reducing concerns that FDA is compromising patient privacy and data security.

FDA has been laying the foundation for the Sentinel System for years through arrangements with healthcare "data owners" that permit it to pose safety-specific questions for evaluation through electronic health records, claims databases, and other information sources. For example, the agency has contracted for several years with UnitedHealth Group's Ingenix, Vanderbilt University, Kaiser Foundation Research Institute, and Harvard Pilgrim Health Care to access pharmacoepidemiologic information that can test hypotheses arising from AE reports. FDA's Center for Biologics Evaluation and Research (CBER) works with CDC, the Veterans Health Administration (VHA), the Centers for Medicare and Medicaid Services (CMS), and large health plans to monitor influenza-vaccine use and related outcomes. FDA also supports the Severe Adverse Events consortium to gain more understanding of the genetic basis of drug-induced serious AEs. Several projects with the Agency for Healthcare Research and Quality aim to assess the use of distributed networks for comparative effectiveness and safety studies.

Evaluating Part D
A new CMS policy now gives FDA access to one billion pharmacy claims per year, collected by the Medicare Part D drug-benefit program, a treasure trove of healthcare-use data (see sidebar "Evaluating Part D"). With additional funds to support postmarket safety surveillance, FDA plans to expand its access to CMS, VHA, and health-plan databases to further expand its ability to detect and assess AEs related to marketed drugs.

Shaping the system

FDA and its partners are beginning to map plans for operating the distributed network, but the details are still "a matter of discussion," said Gerald Dal Pan, director of CDER's Office of Surveillance and Epidemiology, at the DIA annual meeting. FDA, health plans, and database operators expect to establish a charter that defines which entities may join the partnership, what data sources will be used, what queries can be run on the system, who will be able to run queries, how specific evaluations will be paid for, and how privacy will be protected. The idea is for a nonprofit network "convener" such as the Reagan–Udall Foundation or an academic research entity to channel information and queries to the partnership and determine how results will be communicated to network participants and to the general public.

The partnership also will support research into best practices and analytical methods and will establish standards for postmarket assessment, most likely under the direction of a scientific advisory board. Improved statistical methods are needed to establish causality and to distinguish meaningful signals when working with large databases. New models for data aggregation that protect patient privacy will be important for enabling FDA to trace back to individual cases when necessary.

Many of these issues will be examined by an active-surveillance pilot project sponsored by the Pharmaceutical Research and Manufacturers of America (PhRMA). After more than a year in development, the project is being launched as a public–private partnership involving PhRMA, FDA, and the Foundation for NIH, with Woodcock as chair. The aim is to test approaches for organizing and operating a drug-safety query system using a distributed information network. The pilot will be transparent, and all parties—industry, academia, and FDA—will have access to its findings.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here